publicEuropean Medicines Agency · European Union · Updated Jun 24, 2026
ICH E22 Guideline on Patient Preference Studies Comments Overview
Stakeholders, including those involved in labeling and signal management, should consider the published comments to align future processes with the regulatory expectations detailed in the draft ICH E22 guideline.
LabelingSignal ManagementRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, Signal Management Lead, Labeling Lead
verifiedRegulatory action: Consultation
Read impact briefarrow_forward